Revealing New Ground Zero: The Resurgent Respiratory Crisis in Buenos Aires and the Ominous Shadow of Pandemic Rebirth


In a disturbing echo of the events that unfolded in late 2019 with the emergence of Covid-19, the international health community has once again been put on high alert. This time, the center of attention is Buenos Aires, Argentina, where a mysterious respiratory illness is causing severe health complications among the population. This recent outbreak has drawn significant concern due to its similarity to the initial stages of the Covid-19 pandemic, both in the pattern of its emergence and the severity of the symptoms observed.

The Outbreak

The first reports of this new illness came on April 17, 2024, through ProMed, an international public health surveillance system known for its role in early warnings during health crises. According to the alert, approximately 60 individuals in Buenos Aires have developed a severe form of atypical pneumonia over the past 30 days, necessitating critical care. Disturbingly, the majority of these patients are young adults with no significant pre-existing health conditions.

Clinical Presentation

The clinical features of this illness include bilateral consolidative infiltrates visible on chest CT scans, a condition severe enough that many patients require mechanical ventilation and even pronation to assist with breathing. This situation is alarming healthcare professionals due to the rapid deterioration of the patients’ respiratory function, reminiscent of acute respiratory distress syndrome (ARDS), a common complication in severe cases of Covid-19.

Possible Psittacosis Link

A noteworthy aspect of this outbreak is the potential involvement of psittacosis, an infection caused by Chlamydophila psittaci, a bacterium typically associated with birds. Reports indicate that around one-third of the affected individuals have shown symptoms suggestive of psittacosis. Furthermore, psittacosis was confirmed via PCR in 10 of the 60 cases. However, many patients did not report any direct contact with birds, raising questions about the transmission dynamics of the disease. Psittacosis is known to be transmitted to humans primarily through inhalation of dust contaminated with dried secretions or feces from infected birds. Given the urban setting of Buenos Aires, the presence of this disease suggests a possible zoonotic spillover or an unrecognized route of transmission.

Historical and Current Context

This situation bears a stark resemblance to the early days of the Covid-19 pandemic, which also began with reports of a cluster of pneumonia cases of unknown etiology. The current outbreak’s potential for widespread transmission and significant health impacts makes it a critical focus for both national and international health authorities. The similarity in the reporting and initial patterns of the disease highlights the ongoing challenges and the importance of surveillance systems like ProMed in the early detection of emerging infectious diseases.

Epidemiological Investigations and Actions

In response to this outbreak, health authorities in Argentina, along with international bodies like the World Health Organization (WHO), have initiated comprehensive epidemiological investigations. Efforts are underway to trace and test contacts of affected individuals, map the spread of the infection, and understand the transmission mechanisms at play. Health professionals are also rigorously analyzing environmental and other potential factors that could have contributed to this outbreak.

Public Health Measures

Given the severity and the mysterious nature of the disease, several public health measures have been swiftly implemented. These include enhanced surveillance, the establishment of specialized treatment units for severe respiratory infections, and public awareness campaigns advising on precautionary measures similar to those recommended during the early days of Covid-19. Health advisories emphasize the importance of hygiene, the use of protective equipment in potential high-risk settings, and the need for prompt medical attention for respiratory symptoms.

Medical and Scientific Response

The medical community is on high alert, and research efforts are focused on identifying the pathogen responsible for this outbreak. Laboratories are conducting extensive testing to rule out common respiratory pathogens and to pinpoint any novel or re-emerging agents. Collaboration across international borders is crucial in these efforts, as sharing findings and strategies can enhance the understanding and management of the outbreak.

Role of International Health Organizations

International health organizations play a pivotal role in coordinating the response to health emergencies like this. Their involvement ensures that information is disseminated efficiently and that resources are mobilized effectively to address the outbreak. These organizations also assist in standardizing the response across different regions, which is essential for containing the spread of the disease.

Potential for Use as a Bioweapon

The potential for using Chlamydia psittaci as a bioweapon has historical precedents, with exploration by China, the former Soviet Union, and the United States. Specifically, incidents of infection among laboratory technicians through inadvertent aerosolization occurred at Fort Detrick in 1945 and 1961, reflecting its historical consideration as a potential biological agent. At that time, the bacterium was mistakenly classified as a virus due to the absence of advanced microscopic and culture methods​​.

Recent advancements have made it possible to genetically manipulate strains of Chlamydia, such as C. muridarum and C. trachomatis, using chlamydial plasmids. More notably, genetic manipulation efforts have included creating stable transformants of C. pneumoniae and C. psittaci using plasmid shuttle vector systems adapted from C. trachomatis research. These methods, originally intended for benign purposes like expressing green fluorescent protein, could theoretically be used to enhance traits such as antimicrobial resistance​.

Persistent infections of C. psittaci, characterized by the downregulation of certain proteins and differentiation between cellular forms, present further genetic avenues to potentially increase antimicrobial resistance. This persistence, along with low diagnosis rates and underreporting, complicates the understanding and management of its impact as a health threat. Despite this, the actual burden of C. psittaci is often underestimated globally. For example, a metanalysis in 2021 indicated a global prevalence of chlamydial infections in birds around 20%, and human cases in the US have been sporadically reported, with occasional outbreaks linked to poultry farms​​.

Overall, the complexity of C. psittaci’s life cycle and its potential for genetic manipulation highlight its dual-use nature, which poses challenges in terms of public health surveillance and biosecurity.

While the situation in Buenos Aires is evolving, the emergence of this new respiratory illness serves as a reminder of the perpetual threat posed by infectious diseases. The global health community remains vigilant, drawing on lessons from past epidemics to respond effectively. Continued monitoring, research, and international cooperation will be vital in overcoming this challenge and preventing a potential health crisis reminiscent of the Covid-19 pandemic.

TABLE 1 – Psittacosis: A Comprehensive Overview

  • Epidemiological Insights
    • Psittacosis, caused by Chlamydia psittaci, is transmitted via zoonotic routes, primarily affecting the lower respiratory tract in humans.
    • C. psittaci is classified as a Category B biological agent by the CDC due to its moderate ease of dissemination and potential for causing moderate morbidity and low mortality rates.
    • Historical data show a significant mortality rate of up to 50% during the 20th century, with a notable pandemic affecting around 800 individuals in 1929–1930.
    • Preventive measures such as quarantining imported parrots in the US for over 40 years highlight the disease’s potential impact in the absence of effective antimicrobial treatments.
  • Understanding the Pathogen
    • C. psittaci belongs to the Chlamydiaceae family and has various genotypes with host-specific preferences, causing infections in both birds and mammals.
    • Its biphasic developmental cycle involves metabolically inactive elementary bodies (EB) and replicative reticulate bodies (RB), enabling survival outside hosts and intracellular multiplication.
    • The pathogen’s unique growth cycle and resistance to traditional culture methods challenge diagnosis, often requiring genotype-specific real-time PCR for detection.
  • Immune Response and Pathogenesis
    • Research on Chlamydia infections, primarily focused on C. trachomatis, elucidates immune evasion mechanisms and host-pathogen interactions.
    • Chlamydial lipooligosaccharide (LOS) and inclusion membrane proteins (Incs), like CPSIT_0842, play vital roles in immune evasion, host cell survival regulation, and inducing inflammatory responses via TLR-mediated pathways.
  • Reservoirs and Transmission Risks
    • Psittacosis reservoirs include domestic and wild avian species, with recent studies revealing high seroprevalence and novel Chlamydiales strains in wild parrots.
    • Other wildlife like seabirds and zoo animals also carry C. psittaci, highlighting transmission risks to humans and potential agricultural impacts, as seen in poultry farm outbreaks.
  • Clinical Implications in Birds and Mammals
    • Avian chlamydiosis or ornithosis presents diagnostic challenges due to nonspecific symptoms, necessitating preventive measures like antibiotic treatments in psittacine birds and quarantine protocols.
    • Limited data exist on psittacosis in non-human mammals, with reported cases indicating variable clinical manifestations and potential implications for livestock health.

Psittacosis in Humans: Transmission, Clinical Presentation, and Complications

  • Transmission and Risk Factors
    • Psittacosis in humans primarily occurs through exposure to C. psittaci in bird droppings, dried secretions, or aerosolized particles, particularly affecting occupations like poultry farm workers, veterinarians, bird owners, and pet store employees.
    • Other Chlamydia species found in birds, such as C. gallinacea and C. abortus, also pose zoonotic transmission risks, with poultry farmers and those handling infected animals at higher risk.
  • Clinical Presentation and Disease Course
    • The incubation period ranges from 5 to 39 days, with most symptoms appearing within 5-14 days after exposure.
    • Symptoms resemble mild community-acquired pneumonia (CAP) and include fever, headache, dry cough, fatigue, shortness of breath, chills, myalgia, and photophobia.
    • Less common symptoms may include pharyngitis, diarrhea, impaired mental status, pulse-temperature dissociation, splenomegaly, rash, and neurologic manifestations like encephalitis or cranial neuropathies.
    • Dermatologic manifestations such as “Horder spots” may also occur.
  • Complications and Severity
    • Psittacosis can lead to severe complications affecting multiple organ systems, including cardiac involvement (endocarditis, myocarditis), pulmonary disease (respiratory failure), renal disease (acute tubular necrosis, nephritis), liver disease (hepatitis, granulomas), hematologic complications (anemia, thrombocytopenia), neurologic disease (encephalitis, intracranial hypertension), reactive arthritis, and cutaneous manifestations.
    • Severe respiratory illness may necessitate hospital-based ventilation and monitoring, especially in cases of pneumonia.
    • Rare but serious complications like C. psittaci endocarditis and gestational psittacosis, associated with high fetal and maternal mortality rates, underscore the severity of untreated infections.
  • Treatment and Prognosis
    • Prompt treatment with antibiotics, typically doxycycline, is crucial in managing psittacosis and reducing complications.
    • Untreated psittacosis can be fatal, especially in cases of endocarditis or severe respiratory illness requiring intensive care.
    • Awareness of the disease’s potential severity, especially among vulnerable populations and those with occupational exposures, is essential for timely diagnosis and treatment.

Treatment Options and Outcomes in Psittacosis

  • Mortality Rates and Historical Context
    • The current mortality rate for psittacosis is approximately 20% without treatment, contrasting with a 50% mortality rate during the 1930 London outbreak.
    • Effective antimicrobial treatment has reduced mortality rates to as low as 1% with timely intervention, highlighting the importance of prompt diagnosis and treatment.
  • Antimicrobial Therapies
    • Human psittacosis is effectively treated with antibiotics such as doxycycline and tetracycline for 10-14 days, with extended courses up to 21 days in severe cases.
    • Azithromycin and erythromycin are alternative options for individuals where tetracycline is contraindicated, such as pregnant women and children under 8 years old.
    • Fluoroquinolones also show activity against C. psittaci infections, although they are less effective than tetracyclines and macrolides.
    • Intravenous doxycycline hyclate may be necessary for severely ill patients who cannot tolerate oral medications.
  • Treatment Response and Relapse
    • Symptoms typically begin to regress within 24 to 48 hours of initiating antibiotic therapy, leading to a rapid improvement in clinical condition.
    • Relapses of psittacosis have been documented, underscoring the importance of completing the full course of antibiotics and monitoring for recurrent symptoms.
  • Challenges and Treatment Failures
    • While effective antimicrobial therapies have significantly reduced psittacosis cases, treatment failures have been reported with quinolones, highlighting the need for careful selection of antibiotics based on susceptibility testing.
    • Chlamydia species, including C. psittaci, can enter a persistent state in response to antimicrobial stimuli, leading to temporary interruption of the replication cycle and challenges in eradicating the infection completely.
    • The regulatory mechanisms underlying Chlamydia persistence remain unclear, warranting further research into strategies for overcoming treatment resistance and improving therapeutic outcomes.

Timely and appropriate antimicrobial treatment with agents like doxycycline, tetracycline, azithromycin, and erythromycin is crucial in managing psittacosis and reducing mortality rates. However, challenges such as treatment failures with quinolones and the potential for Chlamydia persistence highlight the need for ongoing research and surveillance to optimize treatment strategies, minimize relapses, and improve outcomes in patients with psittacosis.

reference link :


Copyright of
Even partial reproduction of the contents is not permitted without prior authorization – Reproduction reserved


Please enter your comment!
Please enter your name here

Questo sito usa Akismet per ridurre lo spam. Scopri come i tuoi dati vengono elaborati.